RxDoctor Payments DataLook up a doctor →

Andrew Mrowiec, MD

Family Medicine · Aberdeen, MDNPI 1780668640

Payments from drug & device makers

$13,594in general payments, 2019–2025

Across 787 payments — averaging $17.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AstraZeneca$2K
  • AbbVie$1K
  • Amgen$1K
  • Pfizer$1K
  • GSK$1K
  • plus $5K from 36 others

What the payments were for

  • Food & beverage$13,548100%
  • Education$460%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$13,594 in reported general payments places this provider in the 95th percentile of 1,193 family medicine providers in Maryland.

See all family medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$392,807
Medicare patients
479
Services billed
5,003

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide131$122,792
EliquisApixaban65$106,762
Trelegy ElliptaFluticasone/Umeclidin/Vilanter79$96,571
OzempicSemaglutide54$59,815
XareltoRivaroxaban41$56,349
FarxigaDapagliflozin Propanediol43$44,775
JanuviaSitagliptin Phosphate16$24,239
JardianceEmpagliflozin14$20,708
EntrestoSacubitril/Valsartan14$16,882
Breo ElliptaFluticasone/Vilanterol24$15,821
Humalog Kwikpen U-100Insulin Lispro37$10,650
MounjaroTirzepatide11$10,563
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog15$8,476
Ambien CrZolpidem Tartrate12$7,548
Albuterol Sulfate HfaAlbuterol Sulfate137$6,812

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$1,109$133,355142 claims
GSKTrelegy Ellipta, Breo Ellipta, Shingrix, Arnuity Ellipta$1,213$120,402141 claims
PfizerEliquis$1,262$106,76265 claims
Novo NordiskOzempic$1,578$59,81554 claims
Johnson & JohnsonXarelto$535$56,34941 claims
AstraZenecaFarxiga$1,533$44,77543 claims
MerckJanuvia$235$24,23916 claims
Boehringer IngelheimJardiance$362$20,70814 claims
NovartisEntresto$186$16,88214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,193 family medicine providers in Maryland.

Other family medicine in Aberdeen

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →